Literature DB >> 3396644

Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam.

N Y Walton1, D M Treiman.   

Abstract

Status epilepticus (SE) was induced in rats by administration of 3 mmol/kg lithium chloride followed 24 h later by injection of 25 mg/kg pilocarpine. Treatment with 20 mg/kg diazepam was initiated at the time each of four EEG patterns was seen: (i) discrete electrographic seizures; (ii) waxing and waning epileptiform activity; (iii) continuous, high-amplitude, rapid spiking; and (iv) periodic epileptiform discharges (PEDs) on a relatively flat background. Success of diazepam in stopping all seizure activity was predicted by the EEG pattern seen at the time of treatment. All rats treated while displaying discrete electrographic seizures had status stopped with diazepam, but only three of six with waxing and waning epileptiform activity and one of six each with continuous spiking and PEDs. Rats which continued to seize had a decrease in spike amplitude of 74.8 +/- 18.25% following diazepam injection. These data confirm the clinical impression that the longer the duration of status epilepticus, the more difficult it is to control and suggest that the EEG pattern at the time of treatment predicts the probability of success.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396644     DOI: 10.1016/0014-4886(88)90010-6

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  52 in total

1.  Altered residual ATP content in rat brain cortex subcellular fractions following status epilepticus induced by lithium and pilocarpine.

Authors:  N Y Walton; A K Nagy; D M Treiman
Journal:  J Mol Neurosci       Date:  1998-12       Impact factor: 3.444

2.  Susceptibility to Soman Toxicity and Efficacy of LY293558 Against Soman-Induced Seizures and Neuropathology in 10-Month-Old Male Rats.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Eric M Prager; Cara H Olsen; Maria F M Braga
Journal:  Neurotox Res       Date:  2017-08-03       Impact factor: 3.911

Review 3.  Lessons from the laboratory: the pathophysiology, and consequences of status epilepticus.

Authors:  Karthik Rajasekaran; Santina A Zanelli; Howard P Goodkin
Journal:  Semin Pediatr Neurol       Date:  2010-09       Impact factor: 1.636

4.  The limitations of diazepam as a treatment for nerve agent-induced seizures and neuropathology in rats: comparison with UBP302.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Franco Rossetti; Steven L Miller; Maria F M Braga
Journal:  J Pharmacol Exp Ther       Date:  2014-08-25       Impact factor: 4.030

5.  Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus.

Authors:  David E Naylor; Hantao Liu; Claude G Wasterlain
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

6.  Midazolam for refractory status epilepticus in children: higher dosing and more rapid and effective control.

Authors:  Robert C Tasker
Journal:  Intensive Care Med       Date:  2006-09-15       Impact factor: 17.440

7.  Selective changes in hippocampal GABAA receptors during status epilepticus.

Authors:  Gregory C Mathews
Journal:  Epilepsy Curr       Date:  2008 Nov-Dec       Impact factor: 7.500

8.  Electroclinical progression of subtle generalized convulsive status epilepticus: description of a case.

Authors:  José L Fernández-Torre; Eloy Rodríguez-Rodríguez; José L Vázquez-Higuera; Miguel A Hernández-Hernández
Journal:  J Neurol       Date:  2013-10-23       Impact factor: 4.849

9.  Erosion of inhibition contributes to the progression of low magnesium bursts in rat hippocampal slices.

Authors:  M A Whittington; R D Traub; J G Jefferys
Journal:  J Physiol       Date:  1995-08-01       Impact factor: 5.182

10.  A rodent model of human organophosphate exposure producing status epilepticus and neuropathology.

Authors:  W Pouliot; S L Bealer; B Roach; F E Dudek
Journal:  Neurotoxicology       Date:  2016-08-12       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.